PPAR-α Agonist GW7647 Protects Against Oxidative Stress and Iron Deposit via GPx4 in a Transgenic Mouse Model of Alzheimer's Diseases
Alzheimer's disease (AD) is a neurodegenerative disease caused by lipid peroxidation and iron hemostasis of the brain. PPAR-α is regarded as the most encouraging therapeutic approach of several neurodegenerative and metabolic disorders, due to its potent regulatory effects. In this study, we examined the ameliorative effect and the mechanisms of a PPAR-α agonist, GW7647, on the established AD models using APP/PS1 mice and APPsw/SH-SY5Y cells. Through Aβ quantification and behavioral test, we found that GW7647 reduced Aβ burden and improved cognitive defect in APP/PS1 mice. Liquid chromatography-mass spectrometry analysis indicated that GW7647 could enter the brain after oral administration. Neuronal cell death and iron deposit were inhibited, accompanied by decreased lipid peroxidation and inflammation. In an in vitro study of APPsw cells, we found that PPAR-α directly bound with GPx4 intron3 to promote GPx4 transcription and reduced the iron transport capability. Our data suggested that activation of PPAR-α by GW7647 improved the disruption of iron homeostasis in the brain of APP/PS1 mice and alleviated neuronal inflammation and lipid peroxidation, which was possibly related to the upregulated transcription of GPx4 mediated by the interaction of GPx4 noncoding region and the PPAR-α.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
ACS chemical neuroscience - 13(2022), 2 vom: 19. Jan., Seite 207-216 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Qu, Xiao-Xia [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.01.2022 Date Revised 27.01.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acschemneuro.1c00516 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335015409 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335015409 | ||
003 | DE-627 | ||
005 | 20231225224921.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acschemneuro.1c00516 |2 doi | |
028 | 5 | 2 | |a pubmed24n1116.xml |
035 | |a (DE-627)NLM335015409 | ||
035 | |a (NLM)34965724 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Qu, Xiao-Xia |e verfasserin |4 aut | |
245 | 1 | 0 | |a PPAR-α Agonist GW7647 Protects Against Oxidative Stress and Iron Deposit via GPx4 in a Transgenic Mouse Model of Alzheimer's Diseases |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.01.2022 | ||
500 | |a Date Revised 27.01.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Alzheimer's disease (AD) is a neurodegenerative disease caused by lipid peroxidation and iron hemostasis of the brain. PPAR-α is regarded as the most encouraging therapeutic approach of several neurodegenerative and metabolic disorders, due to its potent regulatory effects. In this study, we examined the ameliorative effect and the mechanisms of a PPAR-α agonist, GW7647, on the established AD models using APP/PS1 mice and APPsw/SH-SY5Y cells. Through Aβ quantification and behavioral test, we found that GW7647 reduced Aβ burden and improved cognitive defect in APP/PS1 mice. Liquid chromatography-mass spectrometry analysis indicated that GW7647 could enter the brain after oral administration. Neuronal cell death and iron deposit were inhibited, accompanied by decreased lipid peroxidation and inflammation. In an in vitro study of APPsw cells, we found that PPAR-α directly bound with GPx4 intron3 to promote GPx4 transcription and reduced the iron transport capability. Our data suggested that activation of PPAR-α by GW7647 improved the disruption of iron homeostasis in the brain of APP/PS1 mice and alleviated neuronal inflammation and lipid peroxidation, which was possibly related to the upregulated transcription of GPx4 mediated by the interaction of GPx4 noncoding region and the PPAR-α | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Alzheimer’s diseases | |
650 | 4 | |a GPx4 | |
650 | 4 | |a PPAR-α | |
650 | 4 | |a iron deposit | |
650 | 4 | |a oxidative stress | |
650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
650 | 7 | |a Amyloid beta-Protein Precursor |2 NLM | |
650 | 7 | |a Butyrates |2 NLM | |
650 | 7 | |a GW 7647 |2 NLM | |
650 | 7 | |a Peroxisome Proliferator-Activated Receptors |2 NLM | |
650 | 7 | |a Phenylurea Compounds |2 NLM | |
650 | 7 | |a Presenilin-1 |2 NLM | |
650 | 7 | |a Iron |2 NLM | |
650 | 7 | |a E1UOL152H7 |2 NLM | |
700 | 1 | |a He, Jia-Huan |e verfasserin |4 aut | |
700 | 1 | |a Cui, Zhi-Qiang |e verfasserin |4 aut | |
700 | 1 | |a Yang, Tuo |e verfasserin |4 aut | |
700 | 1 | |a Sun, Xiao-Hong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ACS chemical neuroscience |d 2010 |g 13(2022), 2 vom: 19. Jan., Seite 207-216 |w (DE-627)NLM19578832X |x 1948-7193 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2022 |g number:2 |g day:19 |g month:01 |g pages:207-216 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschemneuro.1c00516 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2022 |e 2 |b 19 |c 01 |h 207-216 |